TABLE 1.

Patient Characteristics for All Eligible Participants and for Subset of Evaluable Participants

Characteristic	Evaluable (n = 201)	Eligible (n = 234)
Sex
Male	128 (63.7%)	150 (64.1%)
Female	73 (36.3%)	84 (35.9%)
Mean age ± SD (y)	64.5 ± 9.7	64.7 ± 9.7
Ethnicity
Hispanic/Latino	6 (3.0%)	7 (3.0%)
Not Hispanic/Latino	189 (94.0%)	217 (92.7%)
Unknown	6 (3.0%)	10 (4.3%)
Race*
White	148 (73.6%)	171 (73.1%)
Asian	26 (12.9%)	31 (13.2%)
Black	22 (10.9%)	27 (11.5%)
Other	9 (4.5%)	9 (3.8%)
Clinical stage
IIIA/IIB	110 (54.7%)	127 (54.3%)
IIIB	91 (45.3%)	107 (45.7%)
Performance status
0	89 (44.3%)	102 (43.6%)
1	112 (55.7%)	132 (56.4%)
Median radiotherapy dose	66 (IQR, 63–68.9)	66 (IQR, 62–69)
Chemotherapy regimen
Carboplatin/paclitaxel	84 (41.8%)	95 (40.6%)
Cisplatin/etoposide	27 (13.4%)	35 (15.0%)
Other	80 (39.8%)	89 (38.0%)
Data not available	10 (5.0%)	15 (6.4%)

^*Multiple races may be endorsed by a single participant, so totals may exceed 100%.